A drug that claimed to treat female sexual desire disorder failed to win approval from a federal advisory panel on Friday.
However, its failure to win votes encouraged the company to continue its research.
The panel’s opposition followed an F.D.A. staff report earlier this week that also recommended against approval.
Such advisory votes do not always influence the [...]